Avidity Partners Management LP Cyteir Therapeutics, Inc. Transaction History

Avidity Partners Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.47 - $1.84 $46,599 - $58,328	-31,700 Reduced 1.77%	1,764,100 $3.21 Million
Q4 2022 Feb 14, 2023	SELL	$1.18 - $1.76 $12,272 - $18,304	-10,400 Reduced 0.58%	1,795,800 $2.96 Million
Q3 2022 Nov 14, 2022	SELL	$1.99 - $4.05 $87,162 - $177,390	-43,800 Reduced 2.37%	1,806,200 $3.47 Million
Q1 2022 May 16, 2022	BUY	$3.39 - $10.51 $1,566 - $4,855	462 Added 0.02%	1,850,000 $6.98 Million
Q4 2021 Feb 14, 2022	BUY	$9.83 - $19.21 $1.63 Million - $3.19 Million	166,097 Added 9.87%	1,849,538 $21 Million
Q3 2021 Nov 15, 2021	SELL	$14.57 - $21.86 $1.82 Million - $2.73 Million	-124,953 Reduced 6.91%	1,683,441 $29.5 Million
Q2 2021 Aug 16, 2021	BUY	$16.8 - $21.4 $30.4 Million - $38.7 Million	1,808,394 New	1,808,394 $38.7 Million

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.